VaxGen plans to relist shares 

South San Francisco biopharmaceutical firm VaxGen Inc. (Pink sheets: VXGN) said it is now current on its financial reporting obligations with the U.S. Security and Exchange Commission and plans to relist its common stock on a nationally recognized stock exchange.

VaxGen has suffered a series of setbacks.

The company, which suffered a well publicized failure of an AIDS vaccine it was developing in 2003, was delisted from the Nasdaq exchange in 2004 for failing to promptly file financial reports with federal authorities as required. It then lost a U.S. government contract to provide an anthrax vaccine in December 2006 after missing a key deadline.

About The Author

Staff Report

Staff Report

Bio:
A daily newspaper covering San Francisco, San Mateo County and serving Alameda, Marin and Santa Clara counties.
Pin It
Favorite

Speaking of Business

More by Staff Report

Latest in Business & Real Estate

© 2018 The San Francisco Examiner

Website powered by Foundation